Academic Journals Database
Disseminating quality controlled scientific knowledge

Grading antiviral therapy in HCV-infected cirrhotic patients

ADD TO MY LIST
 
Author(s): ZHANG Ying

Journal: Journal of Clinical Hepatology
ISSN 1001-5256

Volume: 29;
Issue: 2;
Start page: 93;
Date: 2013;
Original page

Keywords: hepatitis C | chronic | liver cirrhosis | antiviral therapy

ABSTRACT
Chronic hepatitis C (CHC) is a major cause of cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The combination drug regimen of pegylated interferon-alpha (PEG-IFNα) and ribavirin is the approved and well-accepted standard-of-care for CHC. However, CHC patients with decompensated cirrhosis usually have contraindications for the use of PEG-IFNα and ribavirin, and the results of therapy are generally poor. To address China′s high prevalence of hepatitis C virus (HCV)-related cirrhosis, difficulties of implementing liver transplantation, and the higher sustained virological response rate seen in Chinese cirrhotic patients, we developed a grading strategy of antiviral therapy for Chinese patients with HCV-related cirrhosis based upon the clinical practice guidelines published by the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). Clinical application of this strategy demonstrated it to be effective for slowing down the rate of cirrhosis progression, preventing complications of HCV-related liver disease, and improving the patients’ quality of life.
Affiliate Program     

Tango Rapperswil
Tango Rapperswil